KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kiniksa Pharmaceuticals International, plc
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$79.48+0.89 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $6.55B
- P/E (TTM)
- 88.3
- Dividend yield
- –
Ownership
Who owns Kiniksa Pharmaceuticals International's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 39 sales
Net sold $47.84M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 6,787,700 | 14.80% | 13G (passive) amendment | Mar 31, 2026 |
| FMR LLC | 4,854,354 | 10.60% | 13G (passive) | Feb 27, 2026 |
| Rubric Capital Management LP | 3,328,653 | 7.37% | 13G (passive) amendment | Dec 31, 2025 |
| Felix J. Baker | 3,253,341 | 7.00% | 13D (active) amendment | May 21, 2026 |
| BlackRock, Inc. | 2,534,789 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Kevin Tang | 2,178,609 | 5.20% | 13G (passive) | Mar 28, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sanj K. Patel | CHAIRMAN & CEO, Director | 873,914 | 0.56% | Sep 3, 2026 |
| John F. Paolini | CHIEF MEDICAL OFFICER | 68,120 | 0.04% | Sep 3, 2026 |
| Ross Moat | CHIEF OPERATING OFFICER | 14,506 | 0.01% | Sep 3, 2026 |
| Mark Ragosa | CHIEF FINANCIAL OFFICER | 22,189 | 0.01% | Sep 3, 2026 |
| Michael R. Megna | CHIEF ACCOUNTING OFFICER | 29,062 | 0.02% | Sep 3, 2026 |
| Dhiraj H. Malkani | CHIEF STRATEGY OFFICER | – | – | Jul 6, 2026 |
| Eben Tessari | CHIEF STRATEGY OFFICER | 23,976 | 0.02% | Apr 8, 2026 |
| Barry D. Quart | Director | 12,745 | 0.01% | Aug 21, 2026 |
| Richard S. Levy | Director | 22,359 | 0.01% | Aug 4, 2026 |
| G. Bradley Cole | Director | 11,672 | 0.01% | Jul 31, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | 123,820 | 0.08% | Jun 2, 2026 |
| Brothers Life Sciences LP Baker | Director | 2,745,259 | 1.76% | Jun 2, 2026 |
| Felix Baker | Director | – | – | Jun 2, 2026 |
| Julian Baker | Director | 158,117 | 0.10% | Jun 2, 2026 |
| Bros. Advisors Lp Baker | Director | – | – | Jun 2, 2026 |
| Kimberly J. Popovits | Director | 15,345 | 0.01% | Jun 2, 2026 |
| Thomas Malley | Director | 87,312 | 0.06% | Jun 2, 2026 |
| Tracey L. McCain | Director | 15,345 | 0.01% | Jun 2, 2026 |
| 667, L.P. | Director | 132,566 | 0.08% | Jun 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael R. Megna CHIEF ACCOUNTING OFFICER | Sep 3, 2026 | Sale(10b5-1 plan) | −4,600 | $80.30 | $369.38K | 29,062 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Sep 1, 2026 | Option exercise | +1,591 | – | – | 22,189 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Sep 1, 2026 | Option exercise | +3,069 | – | – | 25,258 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Sep 1, 2026 | Tax withholding | −4,404 | $79.28 | $349.15K | 20,854 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Sep 1, 2026 | Option exercise | +1,750 | – | – | 20,598 |
| Mark Ragosa CHIEF FINANCIAL OFFICER | Sep 1, 2026 | Option exercise | +2,694 | – | – | 18,848 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Option exercise | +9,991 | – | – | 86,165 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Option exercise | +6,481 | – | – | 92,646 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Tax withholding | −15,144 | $79.28 | $1.20M | 92,348 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Option exercise | +8,609 | – | – | 107,492 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Option exercise | +6,237 | – | – | 98,883 |
| Michael R. Megna CHIEF ACCOUNTING OFFICER | Sep 1, 2026 | Option exercise | +2,644 | – | – | 39,193 |
| Michael R. Megna CHIEF ACCOUNTING OFFICER | Sep 1, 2026 | Option exercise | +3,932 | – | – | 31,629 |
| Michael R. Megna CHIEF ACCOUNTING OFFICER | Sep 1, 2026 | Option exercise | +2,558 | – | – | 34,187 |
| Michael R. Megna CHIEF ACCOUNTING OFFICER | Sep 1, 2026 | Option exercise | +2,362 | – | – | 36,549 |
| Michael R. Megna CHIEF ACCOUNTING OFFICER | Sep 1, 2026 | Tax withholding | −5,531 | $79.28 | $438.50K | 33,662 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Option exercise | +8,609 | – | – | 107,492 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Option exercise | +9,991 | – | – | 86,165 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Option exercise | +6,481 | – | – | 92,646 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Tax withholding | −15,144 | $79.28 | $1.20M | 92,348 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Sep 1, 2026 | Option exercise | +6,237 | – | – | 98,883 |
| John F. Paolini CHIEF MEDICAL OFFICER | Sep 1, 2026 | Option exercise | +2,497 | – | – | 68,120 |
| John F. Paolini CHIEF MEDICAL OFFICER | Sep 1, 2026 | Tax withholding | −4,029 | $79.28 | $319.42K | 69,922 |
| John F. Paolini CHIEF MEDICAL OFFICER | Sep 1, 2026 | Option exercise | +1,750 | – | – | 71,494 |
| John F. Paolini CHIEF MEDICAL OFFICER | Sep 1, 2026 | Option exercise | +2,457 | – | – | 73,951 |
| John F. Paolini CHIEF MEDICAL OFFICER | Sep 1, 2026 | Option exercise | +1,624 | – | – | 69,744 |
| Ross Moat CHIEF OPERATING OFFICER | Sep 1, 2026 | Option exercise | +2,477 | – | – | 14,506 |
| Ross Moat CHIEF OPERATING OFFICER | Sep 1, 2026 | Option exercise | +1,740 | – | – | 17,857 |
| Ross Moat CHIEF OPERATING OFFICER | Sep 1, 2026 | Option exercise | +2,457 | – | – | 20,314 |
| Ross Moat CHIEF OPERATING OFFICER | Sep 1, 2026 | Tax withholding | −4,007 | $79.28 | $317.67K | 16,307 |
| Ross Moat CHIEF OPERATING OFFICER | Sep 1, 2026 | Option exercise | +1,611 | – | – | 16,117 |
| Barry D. Quart Director | Aug 19, 2026 | Gift | −2,600 | – | – | 12,745 |
| Richard S. Levy Director | Aug 1, 2026 | Option exercise | +403 | – | – | 22,359 |
| G. Bradley Cole Director | Jul 29, 2026 | Sale | −3,673 | $81.43 | $299.09K | 11,672 |
| G. Bradley Cole Director | Jul 29, 2026 | Gift | −4,500 | – | – | 7,172 |
| Michael R. Megna CHIEF ACCOUNTING OFFICER | Jul 15, 2026 | Award | +279 | $33.50 | $9.35K | 27,697 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Jun 1, 2026 | Conversion | +900,000 | – | – | 951,794 |
| G. Bradley Cole Director | May 29, 2026 | Option exercise | +2,799 | – | – | 15,345 |
| Julian Baker Director | May 29, 2026 | Award | +6,078 | – | – | 143,277 |
| Julian Baker Director | May 29, 2026 | Award | +6,078 | – | – | 2,744,894 |
| Barry D. Quart Director | May 29, 2026 | Option exercise | +2,799 | – | – | 15,345 |
| Tracey L. McCain Director | May 29, 2026 | Option exercise | +2,799 | – | – | 15,345 |
| Thomas Malley Director | May 29, 2026 | Option exercise | +2,799 | – | – | 15,345 |
| Kimberly J. Popovits Director | May 29, 2026 | Option exercise | +2,799 | – | – | 15,345 |
| Richard S. Levy Director | May 29, 2026 | Option exercise | +2,799 | – | – | 21,956 |
| John F. Paolini CHIEF MEDICAL OFFICER | May 1, 2026 | Option exercise | +58,424 | $10.36 | $605.27K | 124,047 |
| John F. Paolini CHIEF MEDICAL OFFICER | May 1, 2026 | Sale(10b5-1 plan) | −21,097 | $54.04 | $1.14M | 65,623 |
| John F. Paolini CHIEF MEDICAL OFFICER | May 1, 2026 | Sale(10b5-1 plan) | −37,327 | $53.52 | $2.00M | 86,720 |
| Sanj K. Patel CHAIRMAN & CEO, Director | May 1, 2026 | Sale(10b5-1 plan) | −48,565 | $54.02 | $2.62M | 0 |
| Sanj K. Patel CHAIRMAN & CEO, Director | May 1, 2026 | Option exercise | +48,565 | $30.93 | $1.50M | 48,565 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 30, 2026 | Option exercise | +2,141 | $30.93 | $66.22K | 2,141 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 30, 2026 | Sale(10b5-1 plan) | −2,141 | $54.01 | $115.64K | 0 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 29, 2026 | Option exercise | +22,544 | $30.93 | $697.29K | 22,544 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 29, 2026 | Sale(10b5-1 plan) | −22,544 | $54.01 | $1.22M | 0 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 28, 2026 | Option exercise | +431,904 | $10.36 | $4.47M | 431,904 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 28, 2026 | Option exercise | +51,750 | $30.93 | $1.60M | 483,654 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 28, 2026 | Sale(10b5-1 plan) | −74,635 | $50.43 | $3.76M | 409,019 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 28, 2026 | Sale(10b5-1 plan) | −113,673 | $51.47 | $5.85M | 295,346 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 28, 2026 | Sale(10b5-1 plan) | −243,596 | $52.02 | $12.67M | 51,750 |
| Sanj K. Patel CHAIRMAN & CEO, Director | Apr 28, 2026 | Sale(10b5-1 plan) | −51,750 | $54.02 | $2.80M | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael R. Megna Officer | Sep 3, 2026 | 4,600 | $369.38K | Sep 3, 2026 | Restricted Stock Lapse |
| G. Bradley Cole Director | Jul 29, 2026 | 3,673 | $299.09K | Jul 29, 2026 | Restricted Stock Lapse |
| Eben Tessari Former Affiliate | Jul 29, 2026 | 67,062 | $5.35M | Jul 29, 2026 | Employee Stock Option Exercise |
| John F. Paolini Officer | May 1, 2026 | 58,424 | $3.14M | May 1, 2026 | Employee Stock Option Exercise |
| Sanj K. Patel Officer, Director | Apr 28, 2026 | 344,591 | $17.78M | Apr 28, 2026 | Employee Stock Option Exercise - See Remarks |
| Ross Moat Officer | Apr 9, 2026 | 1,703 | $79.51K | Apr 9, 2026 | Restricted Stock Lapse |
| Michael R. Megna Officer | Apr 9, 2026 | 6,625 | $309.32K | Apr 9, 2026 | Restricted Stock Lapse |
| Sanj K. Patel Officer, Director | Apr 6, 2026 | 219,591 | $10.98M | Apr 6, 2026 | Employee Stock Option Exercise - See Remarks |
| Barry D. Quart Director | Apr 6, 2026 | 20,000 | $1.00M | Apr 6, 2026 | Employee Stock Option Exercise - see remarks |
| Ross Moat Officer | Apr 6, 2026 | 2,367 | $114.99K | Apr 6, 2026 | Restricted Stock Lapse |
| Mark Ragosa Officer | Mar 9, 2026 | 36,722 | $1.69M | Mar 9, 2026 | Employee Stock Option Exercise |
| John F. Paolini Officer | Mar 2, 2026 | 40,000 | $1.79M | Mar 2, 2026 | Employee Stock Option Exercise |
| Barry D. Quart Director | Dec 15, 2025 | 58,889 | $2.44M | Dec 15, 2025 | Employee Stock Option Exercise - see remarks |
| Mark Ragosa Officer | Dec 8, 2025 | 72,686 | $3.02M | Dec 8, 2025 | Employee Stock Option Exercise |
| Eben Tessari Officer | Nov 26, 2025 | 48,384 | $2.08M | Nov 26, 2025 | Employee Stock Option Exercise - See Remarks |